Abstract:BackgroundA useful heterologous production system is required to obtain sufficient amounts of recombinant therapeutic proteins, which are often necessary for chemical characterization and engineering studies on the development of molecules with improved properties. Human Fas ligand extracellular domain (hFasLECD) is an agonistic death ligand protein that has potential applications for medical purposes. Site-specific chemical modifications can provide a powerful means for the development of engineered proteins with beneficial functions. This study aimed to enhance the yield of hFasLECD using a Pichia pastoris secretory expression system suitable for efficient production on a small laboratory scale, and further to provide procedures for its site-specific chemical modification without impairing the biological functions based on the developed production system.ResultsA convenient cultivation system using a disposable plastic bag provided a three-fold increase in purification yield of tag-free hFasLECD as compared with the conventional system using a baffled glass flask. The system was further applied to the production of a mutant, which contains an additional reactive cysteine residue in the N-terminal tag-sequence region. Site-specific conjugations and cross-linking without impairing biological functions were achieved by reaction of the mutant hFasLECD with single maleimide group containing compounds and a linear polyethylene glycol derivative containing two maleimide groups at either end, respectively. All purified tag-free and chemically modified hFasLECDs showed an evident receptor binding activity in co-immunoprecipitation experiments mediated by wild-type and N-glycosylation site deficient mutant human Fas receptor extracellular domain derivatives. An N-Ethylmaleimide conjugated hFasLECD derivative demonstrated a significant cytotoxic activity against human HT-29 colorectal cancer cells.ConclusionsA new, efficient cultivation system for enhanced secretory production of hFasLECD using P. pastoris and an effective strategy for site-specific chemical modifications of hFasLECD were devised. The results obtained constitute the basis for biomedical applications including developments of novel therapeutic proteins and diagnostic tools targeted to related diseases and their biomarkers.

Synthesis of N‐Glycosylated Soluble Fas Ligand

Considering Fas ligand as a target for therapy.

The Fas Ligand As a Cell Death Factor and Signal Transducer

Activation‐dependent FasL Expression in T Lymphocytes and Natural Killer Cells

Slowly getting a clue on CD95 ligand biology.

The Adaptor Protein Nck Interacts with Fas Ligand: Guiding the Death Factor to the Cytotoxic Immunological Synapse

Improved production of recombinant human Fas ligand extracellular domain in Pichia pastoris: yield enhancement using disposable culture-bag and its application to site-specific chemical modifications

Human Fas ligand extracellular domain: current status of biochemical characterization, engineered-derivatives production, and medical applications

A Computational and Chemical Design Strategy for Manipulating Glycan‐Protein Recognition

Modulating antibody effector functions by Fc glycoengineering

[Expression of the Soluble Human Fas Ligand in Dictyostelium Discoideum].

Reprogramming the Enzymatic Assembly Line for Site-Specific Fucosylation

Regulation of FasL Expression: A SH3 Domain Containing Protein Family Involved in the Lysosomal Association of FasL

Thermally Triggered, Cell-Specific Enzymatic Glyco-Editing: <i>In Situ</i> Regulation of Lectin Recognition and Immune Response on Target Cells

Chemical Synthesis of Homogeneous Human E-Cadherin N-Linked Glycopeptides: Stereoselective Convergent Glycosylation and Chemoselective Solid-Phase Aspartylation.

Enzyme-Sialylation-Controlled Chemical Sulfation of Glycan Epitopes for Decoding the Binding of Siglec Ligands

Synthesis of lipid-linked oligosaccharides by a compartmentalized multi-enzyme cascade for the in vitro N-glycosylation of peptides

Targeted protein degradation through site-specific antibody conjugation with mannose 6-phosphate glycan

Efficient purification of soluble receptor for advanced glycation end-products from Sus scrofa lung tissue and synthesis of its binding ligand, glycated bovine serum albumin

High yield purification of an Isoleucine zipper modified CD95 Ligand with either biotin or DNA-oligomer binding domain for efficient Cell Apoptosis Induction

Immobilized enzyme cascade for targeted glycosylation